C Sixty Inc. is a leading nanomedicine company pioneering the development of biopharmaceutical applications of fullerenes, a unique class of small molecules with unprecedented antioxidant properties.

Read more about

News

C Sixty and University of Texas Health Science Center Test Nanotech Mode of Drug Delivery: Researchers Test Nanotech Mode of Drug Delivery (June 15, 2004)

Smalltimes.com: Companies enter deals to test drugs for diseases in the brain (Dec. 3, 2003)

Smalltimes.com: Buckyballs make it to the big time (Oct. 17, 2003)

C Sixty and Merck sign agreements to develop fullerene drugs:
Merck will license fullerene compounds for animal studies, with exclusive option to market drugs. (press release - Oct. 16, 2003)